- Number of people
- 79 (84.81% female)
- People with ≥2 records
- 3.80%
- Median duration from first to last measurement
- — years
Pineapple IgE Ab [Units/volume] in Serum
Coding
Definition
- OMOP Concept ID
- 3021661— open in OHDSI Athena.
- Part of collection
- Pineapple (Ananas comosus) IgE with 0 other OMOP concept — open in OHDSI Athena.
OMOP mapping QC
| OMOP concept ID | Test name | Measurement unit (harmonized unit) | N people | N records | Missing measurement value | Harmonized value distribution |
Test outcome
NA
N
A
AA
L
LL
H
HH
|
|---|---|---|---|---|---|---|---|
| 3021661 | s-ananase | kU/l (u/ml) | 43 | 44 | 0.00% |
|
|
| 3021661 | s-ananase | — (—) | 36 | 37 | 100.00% | Distribution not available |
Cohort
- Number of people
- 79 (84.81% female)
Year of birth distribution
Age at first measurement
Age at last measurement
Age at start of registry
Duration from first to last measurement
Statistics
- People with ≥2 records
- 3.80%
- Median number of measurements per person
- 1.0
- Median duration from first to last measurement
- —
Number of measurements over the years
Number of measurements per person
Distribution of lab values
Reference range
N people
N records
—
55
57
<0.35/KAIKKI
16
16
Value range per person
LabWAS
Endpoint
People with measurements
Mean N measurements
Mean measured value
Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
31
6.45
17.06
1.0
1.1
0.15
0.19
u/ml
0.12
23
15
25
15
9.21
15.13
1.0
1.1
0.19
0.40
u/ml
—
19
5
34
44
4.28
10.95
1.0
1.0
0.19
0.14
u/ml
0.18
20
23
20
21
9.16
9.94
1.0
1.0
0.19
0.03
u/ml
1.07
11
11
20
27
3.71
5.32
1.0
1.0
0.10
0.30
u/ml
—
10
15
17
46
3.54
5.25
1.0
1.1
0.30
0.16
u/ml
—
7
26
14
13
5.50
4.63
1.0
1.0
0.11
0.08
u/ml
—
9
5
12
21
5.51
4.59
1.0
1.0
0.13
0.29
u/ml
—
6
11
17
50
3.21
4.54
1.1
1.0
0.04
0.20
u/ml
1.22
11
23
16
43
3.36
4.54
1.1
1.0
0.05
0.19
u/ml
—
10
22
22
42
2.98
4.53
1.0
1.0
0.08
0.23
u/ml
0.77
11
25
17
42
3.26
4.47
1.0
1.0
0.18
0.13
u/ml
0.12
12
20
14
34
4.12
4.19
1.0
1.0
0.10
0.22
u/ml
—
9
14
20
46
2.90
4.16
1.0
1.0
0.17
0.12
u/ml
0.16
14
22
13
13
5.07
4.09
1.0
1.0
0.14
0.08
u/ml
—
7
5
11
25
4.40
3.61
1.0
1.0
0.13
0.27
u/ml
—
6
11
21
54
2.49
3.34
1.0
1.0
0.07
0.18
u/ml
0.69
11
30
17
46
2.50
2.80
1.0
1.0
0.10
0.23
u/ml
—
9
24
18
50
2.40
2.73
1.1
1.0
0.10
0.22
u/ml
0.58
12
24
17
41
2.50
2.72
1.0
1.0
0.03
0.18
u/ml
1.12
11
24
11
36
3.05
2.55
1.0
1.0
0.15
0.17
u/ml
—
6
19
18
54
2.25
2.42
1.0
1.0
0.04
0.20
u/ml
—
10
31
16
52
2.24
2.18
1.0
1.1
0.09
0.20
u/ml
—
8
27
20
57
2.07
2.16
1.0
1.1
0.27
0.12
u/ml
0.39
12
31
17
43
2.10
1.87
1.0
1.0
0.13
0.22
u/ml
0.35
12
21
19
54
1.96
1.79
1.0
1.0
0.14
0.18
u/ml
—
10
30
15
37
2.12
1.69
1.1
1.0
0.04
0.17
u/ml
—
10
20
16
63
1.98
1.67
1.0
1.0
0.04
0.20
u/ml
1.59
11
33
13
58
2.00
1.45
1.0
1.1
0.09
0.17
u/ml
—
8
31
16
43
1.91
1.42
1.0
1.0
0.16
0.22
u/ml
—
10
21
12
40
1.89
1.12
1.0
1.0
0.02
0.23
u/ml
—
6
20
12
42
1.65
0.76
1.1
1.0
0.04
0.20
u/ml
—
6
23
13
49
1.55
0.66
1.0
1.1
0.08
0.19
u/ml
—
7
26
13
49
1.55
0.66
1.0
1.1
0.08
0.19
u/ml
—
7
26
14
48
1.51
0.63
1.0
1.0
0.29
0.14
u/ml
—
9
24
15
51
1.47
0.61
1.0
1.0
0.10
0.20
u/ml
—
10
25
13
58
1.49
0.59
1.0
1.0
0.08
0.19
u/ml
—
7
31
14
48
1.47
0.57
1.0
1.1
0.12
0.11
u/ml
—
7
26
Vertebral, anorectal, cardiavascular, thracheoesophagial, renal and limb anomaly, including avohilmo
0
12
0.00
0.21
0.0
1.0
—
0.07
—
0
5
0
12
0.00
0.21
0.0
1.0
—
0.07
—
0
5